(Q48430413)

11 February 2018

title

Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. (English)

1 reference

11 February 2018

0 references

0 references

John P Blass

1

1 reference

11 February 2018

publication date

1 November 2002

1 reference

11 February 2018

published in

Neurobiology of Aging

1 reference

11 February 2018

volume

23

1 reference

11 February 2018

issue

6

1 reference

11 February 2018

page(s)

1077-1084

1 reference

11 February 2018

Alzheimer's disease: genes, proteins, and therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

The relative frequency of "dementia of unknown etiology" increases with age and is nearly 50% in nonagenarians

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Aging and Alzheimer's disease: lessons from the Nun Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Absence of vascular dementia in an autopsy series from a dementia clinic.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Translating the knowledge of molecular alterations that occur during colon carcinogenesis into clinically relevant solutions

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Dementia with bilateral medial temporal lobe ischemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Neurodegenerative tauopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Genes, models and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Aging effect on psychosocial outcome in traumatic brain injury.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Oxidative damage is the earliest event in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Immunologic treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Cellular signaling roles of TGF beta, TNF alpha and beta APP in brain injury responses and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Autoantibodies to amyloid-beta and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Brain infarction and the clinical expression of Alzheimer disease. The Nun Study

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

White matter volumes and periventricular white matter hyperintensities in aging and dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type: A Congophilic Angiopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Inflammation and Alzheimer's disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Reactive oxygen species, cell signaling, and cell injury

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Cerebrometabolic aspects of delirium in relationship to dementia

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Abnormalities of mitochondrial enzymes in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA).

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

The mitochondrial spiral. An adequate cause of dementia in the Alzheimer's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

The role of the metabolic lesion in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Oxidative stress and a key metabolic enzyme in Alzheimer brains, cultured cells, and an animal model of chronic oxidative deficits

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

The alpha-ketoglutarate dehydrogenase complex

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Modulation byDLST of the genetic risk of Alzheimer's disease in a very elderly population

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Oxidative modification of glutamine synthetase by amyloid beta peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900036-2

7 January 2021

10.1016/S0197-4580(02)00036-2

Identifiers

DOI

1 reference

11 February 2018

release_62uwnkumurcgbemz3tebbn2rfy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/62uwnkumurcgbemz3tebbn2rfy

24 November 2022

mapped directly with Wikidata item

PubMed ID

12470805

1 reference

11 February 2018